The current status of thalidomide in the management of multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaFollow-up psychophysical studies in bortezomib-related chemoneuropathy patients.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome
P2860
The current status of thalidomide in the management of multiple myeloma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The current status of thalidomide in the management of multiple myeloma.
@ast
The current status of thalidomide in the management of multiple myeloma.
@en
type
label
The current status of thalidomide in the management of multiple myeloma.
@ast
The current status of thalidomide in the management of multiple myeloma.
@en
prefLabel
The current status of thalidomide in the management of multiple myeloma.
@ast
The current status of thalidomide in the management of multiple myeloma.
@en
P356
P1433
P1476
The current status of thalidomide in the management of multiple myeloma.
@en
P2093
Axel Glasmacher
Marie von Lilienfeld-Toal
P356
10.1159/000087037
P478
114 Suppl 1
P577
2005-01-01T00:00:00Z